MedTrace Logo

Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

NCT07374614 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2026-01-29

No results posted yet for this study

Summary

This observational study aims to evaluate the real-world effectiveness and safety of iruplinalkib in patients with advanced ALK-positive lung adenocarcinoma who have progressed on or are intolerant to prior lorlatinib therapy. The results are expected to provide real-world evidence to inform clinical decision-making for this heavily pretreated patient population.

Conditions

Interventions

DRUG

Iruplinalkib tablets

180mg, QD

Sponsors & Collaborators

  • Shenzhen People's Hospital

    collaborator OTHER

  • Longgang District People's Hospital of Shenzhen

    collaborator OTHER

  • Sun Yat-sen University Cancer Hosptial

    collaborator UNKNOWN

  • Eighth Affiliated Hospital, Sun Yat-sen University

    collaborator OTHER

  • The First Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • People Hospital of New District Longhua Shenzhen

    collaborator UNKNOWN

  • Peking University Shenzhen Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07374614 on ClinicalTrials.gov